Exhibit 99.1

  Corniche Group Appoints Dr. Wayne A. Marasco, Harvard Immunology Researcher
                    and Professor, to Its Board of Directors

    MELVILLE, N.Y., June 5 /PRNewswire-FirstCall/ -- Corniche Group
Incorporated (OTC Bulletin Board: CNGI) today announced that Wayne A. Marasco,
Associate Professor in the Department of Cancer Immunology & AIDS at
Dana-Farber Cancer Institute and Associate Professor of Medicine in the
Department of Medicine, Harvard Medical School, has been elected to its board
of directors.

    "We are delighted to announce the appointment of Wayne Marasco, a
distinguished scientist and leading expert in AIDS and cancer research, to our
board," said Mark Weinreb, Corniche's president and CEO. "Wayne has over 20
years experience in academic and immunological research and his knowledge and
expertise will be invaluable to Corniche in the development and implementation
of its new business strategy."

    Dr. Marasco, M.D., Ph.D. is a board-certified physician specializing in
the treatment of immunocompromised (cancer, bone marrow and solid organ
transplants) and HIV-1 infected patients. Dr. Marasco is also the principal
investigator of several studies funded by the National Institutes of Health in
the areas of AIDS, gene therapy and therapeutic monoclonal antibody
development. The Marasco research laboratories are primarily focused on the
areas of antibody engineering and gene therapy for the treatment of
HIV-1-infection, Adult T-cell Leukemia and Breast Cancer.

    In 1995, Dr. Marasco founded IntraImmune Therapies, Inc. (ITI) a gene
therapy and antibody engineering company. He served as the Chairman of the
Scientific Advisory Board (SAB) until the company was acquired by Abgenix in
2000. He has also served as a scientific advisor to several biotechnology
companies working in the field of antibody engineering, gene discovery and
gene therapy. He is the inventor on numerous issued and pending patents.

    Dr. Marasco earned his B.A. in biology from Millersville State College,
his Ph.D. in immunology from the University of Connecticut, and his M.D. from
the University of Michigan Medical School. He received his postdoctoral
training at the University of Michigan Medical School, Harvard Medical School,
Brigham and Women's Hospital and the Dana-Farber Cancer Institute.

    Corniche recently announced a strategic change in direction to focus on
building a business in the medical sector. Corniche will seek to exploit value
from assets and opportunities in the medical sector by acquiring or
participating in biotech and medical companies and technologies. Corniche will
focus on new technology developments and may participate in or acquire the
rights to new drugs and medical devices currently under development by smaller
independent Biotechnology companies, medical institutions and medical
researchers.

    This release contains forward-looking statements made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements represent management's judgment regarding future
events.  Although management believes that the expectations reflected in such
statements are reasonable, they give no assurance that such expectations will
prove to be correct and you should be aware that actual results could differ
materially from those contained in the forward-looking statements due to a
number of factors. Corniche undertakes no obligation to update or revise the
information contained in this release, whether as a result of new information,
future events or circumstances or otherwise.